Clinical Pearls

Brittany Albright, MD, MPH, and Kristian Dambrino, DNP, PMHNP-BC, discuss the difference between major depressive disorder and treatment-resistant depression, plus monoaminergic versus glutamatergic treatments.

In this video, Hara Oyedeji, APRN, PMHNP-BC, MSEd, offers guidance to APPs navigating LAI initiation while considering oral overlap requirements in the treatment of schizophrenia.

In part 2 of this series, Hara Oyedeji, APRN, PMHNP-BC, MSEd, unpacks the use and benefits of xanomeline-trospium as a treatment option for schizophrenia.

In this video, Hara Oyedeji, APRN, PMHNP-BC, MSEd, explores how APPs can most effectively prescribe and monitor patient progress on clozapine, the only FDA-approved treatment for treatment-resistant schizophrenia.

In part 1 of this series, Julie Carbray, PhD, PMHNP-BC, PMHCNS-BC, APRN, and Kristian Dambrino, DNP, PMHNP-BC, discuss the role NMDA and AMPA receptors play in rapid-acting depression treatment.

In this video, Craig Chepke, MD, DFAPA, discusses effective communication strategies clinicians can use when introducing long-acting injectable (LAI) antipsychotics to patients for the treatment of schizophrenia.

2025 Psych Congress NP Institute Co-Chair Julie Carbray, PhD, PMHNP-BC, PMHCNS-BC, APRN, shares how clinicians can best navigate between stimulant and nonstimulant treatment options for patients with ADHD.

Psych Congress Faculty Member Kristian Dambrino, DNP, PMHNP-BC, dives into the nuances of prescribing vesicular monoamine transporter 2 (VMAT-2) inhibitors for the long-term management of TD.

In this interview from the NP Institute annual meeting, Co-Chair Andrew Penn, NP, discusses the importance of neurobiological foundations in everyday prescribing.

Anxiety in women is often misunderstood—even in psychiatric clinical settings. Ahead of the 2025 Psych Congress NP Institute, Psych Congress Network connected with Moushumi Mukerji, MSN, PMHNP-BC, CNM, to discuss some of the key clinical...